Medpace Holdings, Inc. (MEDP) Stock Price & How to Invest

Medpace Holdings is a full-service, global clinical contract research organization that designs and runs Phase I through Phase IV clinical trials for biotechnology, pharmaceutical, and medical device companies. The business is deliberately concentrated on small and mid-sized biotech sponsors and complex therapeutic areas, and it employs roughly 6,300 people across more than 40 countries. Unlike larger peers that grow heavily through acquisition, Medpace has scaled organically, which has helped it post unusually strong margins and returns on capital for the sector.

The investment picture in 2026 is a contrast between excellent operating quality and softening leading indicators. Revenue is still growing at a double-digit pace and profitability remains high, but net book-to-bill has dipped below 1.0 as trial cancellations rose to the highest level in more than a year, raising questions about the pace of future revenue. Layered on top is a market-wide worry that AI tools could reduce the labor content of running trials and pressure CRO pricing over time, which drove a large valuation reset off the stock's highs.

The biggest near-term concern is booking softness: net book-to-bill fell to roughly 0.88 in Q1 2026 as cancellations hit a multi-quarter high, which can slow future revenue if it persists. Medpace's heavy exposure to small and mid-cap biotech makes it sensitive to swings in biotech funding and sentiment. A market-wide fear that AI will reduce the labor and pricing of clinical trials has compressed CRO valuations, and management itself expects AI spending to exceed savings through 2026-2027. Trial cancellations, delays, and sponsor consolidation can create lumpy results, and competition from far larger CROs (IQVIA, ICON, and others) is intense. The stock has been volatile, falling sharply from its 52-week high.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Medpace Holdings, Inc.'s investor relations page or your broker.

• Q1 2026 revenue: ~$707M (up ~26.5% YoY)
• Q1 2026 diluted EPS: ~$4.28
• 2026 revenue guidance: ~$2.76-2.86B
• 2026 EPS guidance: ~$16.68-17.50
• EBITDA margin: ~21%
• Forward P/E: ~24x

Medpace beat on earnings but the stock fell sharply after Q1 2026 as net book-to-bill dropped below 1.0 and cancellations rose. Shares had already declined roughly a third from their 52-week high (near $629) toward the low $400s amid AI-disruption fears. The forward multiple has compressed from higher pre-selloff levels while the company still guides to high-single to low-double-digit revenue growth.

There are three common ways to get MEDP exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so MEDP sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where MEDP fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Medpace pairs standout profitability and capital efficiency with genuine near-term booking and AI-disruption questions, so the debate is durable execution versus a slowing new-business pipeline.

Whether MEDP is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MEDP a buy?, and where the stock could go from here in the MEDP stock forecast.

For income investors, whether MEDP pays a dividend and how the payout looks is covered in does MEDP pay a dividend?